Pacific Edge Reports Resilient FY25 Performance Amid Medicare Challenges

The latest announcement is out from Pacific Edge Limited ( (PFGTF) ).

Pacific Edge Limited reported a resilient financial performance for the fiscal year ending March 2025, despite challenges with Medicare coverage. The company announced a NZ$20 million equity raising to capitalize on clinical and commercial milestones and aims to regain Medicare coverage for its tests. Operating revenue decreased by 8.6% to $21.8 million due to Medicare uncertainty, and total laboratory throughput of Cxbladder tests fell by 11.5%. Despite these challenges, the company achieved significant strategic progress, including the inclusion of Cxbladder Triage in the American Urological Association guidelines with a ‘Grade A’ evidence rating. The company is positioned for revenue growth in the US with a draft Medicare price set for Cxbladder Triage Plus, and it is advancing the commercialization of its tests with a focus on non-Medicare revenue streams.

More about Pacific Edge Limited

Pacific Edge Limited is a cancer diagnostics company specializing in non-invasive bladder cancer diagnostics. The company is known for its Cxbladder tests and focuses on regaining Medicare coverage while expanding in non-Medicare channels.

For an in-depth examination of PFGTF stock, go to TipRanks’ Stock Analysis page.